top of page

Janssen’s niraparib received breakthrough designation for metastatic castration-prostate cancer

Updated: Oct 6, 2019

Janssen's niraparib, an orally-administered poly ADP-ribose polymerase (PARP) inhibitor received breakthrough designation from the US FDA. The drug is indicated in patients suffering from BRCA1/2 gene-mutated metastatic castration-resistant prostate cancer (mCRPC); who were previously treated with taxane chemotherapy and androgen receptor (AR)-targeted therapy.

The approval was based on GALAHAD study, a Phase 2, multicenter, open-label clinical trial.

More on Janssen

BRCA1/2 mutations are the most common DNA-gene defects. The primary endpoint was the objective response rate. The study included 46 patients with BRCA mutation and 35 patients with non-BRCA mutated mCRPC. Overall response rate was 41%, CRR was 63% in BRCA mutated patients. Objective response rate was 5.5 months. In non-BRCA patients, CRR was 17%, objective response was reported in two patients and the duration was 3.8 and 6.5 months.

The results were reported in ESMO2019.

More about ESMO2019


Recent Posts

See All

GlaxoSmithKline (GSK) has presented positive results from the phase III trial of its MenABCWY vaccine candidate at the European Society for Paediatric Infectious Diseases. The vaccine combination was

bottom of page